Спектр нарушений состояния костной ткани у больных III и IV стадий хронической болезни почек

1. Клинические рекомендации. Остеопороз. 
Диагностика, профилактика и лечение. Под ред. О.М.Лесняк, Л.И.Беневоленской. М.: Гоэтар-Медиа, 2009; 204–18.
2. Михайлов Е.Е., Беневоленская Л.И., Мылов Н.М. Распространенность переломов позвоночника в популяционной выборке лиц 50 лет и старше. Вестн. травматол. и ортопед. им. Н.Н.Приорова, 1997; 3: 20–7.
3. Ahmed AIH, Blake GM, Rymer JM, Fogelman I. Screening for osteopenia and osteoporosis: Do accepted normal rangeslead to overdiagnosis? Osteoporosis Int 1997; 7: 432–8.
4. Bonnic SL. Bone Densitometry in Clinical Practice. Humana Press Inc. 2004.
5. Brown JP, Josse RG. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 suppl.): S51–34.
6. Coen G, Mazzaferro S, Ballanti P et al. Renal bone disease in 76 patients with varying degees of predialysis chronic renal failure: a cros-sectional study. NDT 1996; 11: 813–9.
7. Craver L, Marco M, Martinez I et al. Mineral metabolism parameters throughout chronic kidney disease stages 1–5 achivement of K/DOQI taget ranges. NDT 2007; 22: 1171–5.
8. Gomes KP, Barello Silva MI, Lette Duarte ME et al. Bone disease in patients with chronic kidney disease under conservative management. Sao Paulo Med J 2005; 123: 83–7.
9. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial 2005; 18: 266–75.
10. Khan AA, Hodsman AB, Papaioannou A et al. Management of osteoporosis in men: an update and case example. 2007.
11. Lob?o R, Carvalho AB, Cuppari L et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol 2004; 62 (6): 432–9.
12. Menon V, Greene T, Pereira A et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005; 46: 455–63.
13. Neves KR, Graciolli FG, dos Reis LM et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function and bone in rats with renal failure. Kidney Int 2004; 66: 2237–44.
14. NKF-K/DOQI Clinical Practice Guidelinesfor bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: 1–201.
15. Official Positions of the International Societyfor Clinical Densitometry. Copyright ISCD, October 2007, Supersedes all prior «Official positions» publications.
16. Ramos AM, Albalate M, Vazquez S et al. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. Kidney Int 2008; 74 (Suppl. 111): S88–93.
17. Rix M, Andreassen H, Eskildsen P et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56: 1084–93.
18. Shin SK, Kim DN, Kim HS et al. Renal osteodistrophy in pre-dialysis patients: ethnic difference? Proceedings of the ICPD’98 – The VIIIth Congress of the ISPD, August 23–26, 1998, Seoul, Korea. Copyright & copy: 1999 International Society for Peritoneal Dialysis. Printed in Canada.
19. Varenna M, Binelli L, Zucchi F et al. Prevalence of osteoporosis by educational level in cohortof menopausal women. Osteoporosis Int 1999; 9: 236–41.
20. Voormolen N, Noordzij M, Grootendorst D et al. The PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. NDT 2007; 22: 2909–16.